Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICONIC-PsA 2: Phase 3 study of icotrokinra in active psoriatic arthritis
CTR20244975Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of icotrokinra in psoriatic arthritis (PsA), sponsored by Janssen Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
icotrokinra
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on CTR20244975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244975.